skip to search skip to navigation skip to main content


Astellas is a major player in the transplantation community. Its products are recognised worldwide in the prevention of organ rejection following kidney, liver and heart transplantation.

Astellas remains focused on investing in its pipeline of potential future immunosuppressant therapies. Through sustained investment in almost 100 European clinical studies, we are continually striving to advance transplant care by developing both new treatment regimes and innovative therapies that target specific pathways.

We are also proud to be able to support patient organisations, helping to offer hope for the future.

NPR17018Ukb – June 2018

Learn more about our therapy areas:

Privacy Policy  |  Terms of Use  |  Cookies Policy Copyright © 2019 Astellas Pharma